Regenxbio's Duchenne gene therapy shows improved muscle function in trial
11/03/2026 15:59
March 11 (Reuters) - Regenxbio RGNX.O said on Wednesday that an interim data from a early-to-mid stage study of its experimental gene therapy in patients with Duchenne muscular dystrophy showed continued improvement in muscle function and a clean safety profile. (Reporting by Kamal Choudhury in Bengaluru) ((Kamal.Choudhury@thomsonreuters.com;))